$4.24 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$25.04 - $64.37The lowest and highst price in the last 52 weeks.
-7.14xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Market Cap||$4.24 Billion|
|Enterprise Value||$3.56 Billion|
|Dividend Yield||$0.00 (0.0%)|
|1 Year Return||-52.0%|
|Outstanding Shares||141 Million|
|Avg 30 Day Volume||1.07 Million|
|Earnings per Share||-$4.22|
|Price to Sales Ratio||7.47|
|Price to Book Ratio||9.96|
|Revenue to Enterprise Value||5.38|
|EBIT to Enterprise Value||-13.01|
|Total Debt to Enterprise Value||0.37|
|Debt to Equity||2.46|
|Gross Profit||$649 Million|
|Net Income||-$593 Million|
|Quarterly Earnings Growth (YoY)||+166.5%|
|Return on Equity||-111.86%|
|Return on Assets||-24.58%|
|Return on Invested Capital||-12.81%|
4,334 shares sold (1 transactions)
CEO: Brett Monia
Industry: Pharmaceutical Preparation Manufacturing
Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and WAYLIVRA and has 4 drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis. The company was named Isis Pharmaceuticals until December 2015.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)s stock price hit a new 52-week low during trading on Tuesday . The stock traded as low as $27.07 and last traded at...Transcript Daily, about 2 months ago
Bard Financial Services Inc. bought a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in the third quarter, according to the company in i...Dakota Financial News, about 2 months ago
Wall Street brokerages expect Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) to post earnings of $0.08 per share for the current quarter, according to Zacks. Six ...Transcript Daily, about 2 months ago
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) shares, rose in value on Friday, 11/26/21, with the stock price down by -2.39% to the previous days close as strong ...Stocks Register, about 2 months ago